Your session is about to expire
← Back to Search
Phosphodiesterase-4 (PDE-4) Inhibitor
Crisaborole for Atopic Dermatitis
Phase 4
Waitlist Available
Research Sponsored by Massachusetts General Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at days 1, 8,15, 21 and 29
Awards & highlights
Summary
The purpose of this study is to document the timing of improvement in atopic dermatitis symptoms and severity following the application of crisaborole ointment 2% in patients 2 years or older with mild to moderate atopic dermatitis. Crisaborole ointment 2% will be applied topically twice daily for four weeks and progress will be assessed by photography and patient-reports.
Eligible Conditions
- Atopic Dermatitis
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ at days 1, 8,15, 21 and 29
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at days 1, 8,15, 21 and 29
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Time to success (by week) on ISGA
Time to success (in days) on ISGA
Trial Design
1Treatment groups
Experimental Treatment
Group I: CrisaboroleExperimental Treatment1 Intervention
Crisaborole is a low molecular weight benzoxaborole PDE-4 inhibitor for the treatment of mild-to-moderate atopic dermatitis in adults and children 2 years and above. Crisaborole ointment 2% is topically applied as a thin layer twice daily for 4 weeks to all AD lesions.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Crisaborole
FDA approved
Find a Location
Who is running the clinical trial?
PfizerIndustry Sponsor
4,625 Previous Clinical Trials
14,284,044 Total Patients Enrolled
Massachusetts General HospitalLead Sponsor
2,993 Previous Clinical Trials
13,230,571 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger